{
  "id": "601cbbf11cb411341a00002a",
  "type": "summary",
  "question": "What is the mechanism of action of Vericiguat?",
  "ideal_answer": "Vericiguat is a stimulator of soluble guanylate cyclase. It was developed for treatment of chronic heart failure with reduced ejection fraction.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31096775",
    "http://www.ncbi.nlm.nih.gov/pubmed/34410527",
    "http://www.ncbi.nlm.nih.gov/pubmed/34074190",
    "http://www.ncbi.nlm.nih.gov/pubmed/34478114",
    "http://www.ncbi.nlm.nih.gov/pubmed/34086190",
    "http://www.ncbi.nlm.nih.gov/pubmed/33770393",
    "http://www.ncbi.nlm.nih.gov/pubmed/34157357",
    "http://www.ncbi.nlm.nih.gov/pubmed/33032741",
    "http://www.ncbi.nlm.nih.gov/pubmed/29032136",
    "http://www.ncbi.nlm.nih.gov/pubmed/34431706",
    "http://www.ncbi.nlm.nih.gov/pubmed/33030703",
    "http://www.ncbi.nlm.nih.gov/pubmed/34291399",
    "http://www.ncbi.nlm.nih.gov/pubmed/33850913",
    "http://www.ncbi.nlm.nih.gov/pubmed/28586537",
    "http://www.ncbi.nlm.nih.gov/pubmed/33395323",
    "http://www.ncbi.nlm.nih.gov/pubmed/32749493",
    "http://www.ncbi.nlm.nih.gov/pubmed/27545139",
    "http://www.ncbi.nlm.nih.gov/pubmed/32222134",
    "http://www.ncbi.nlm.nih.gov/pubmed/32458378"
  ],
  "snippets": [
    {
      "text": "Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32458378",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32458378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32749493",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Following the positive results of the phase 3 VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial on the sGC stimulator vericiguat in HFrEF, the main open questions are the efficacy of the sacubitril/valsartan-vericiguat combination in HFrEF and of vericiguat in HFpEF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33032741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat, a direct stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for symptomatic chronic heart failure (HF) and ejection fraction\u2009<\u200945%.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33030703",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conversely, sGC stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, and then exert a more physiological action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34291399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conversely, sGC stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, thus exerting a more physiological action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34410527",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background The VITALITY-HFpEF trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved Ejection Fraction) is designed to determine the efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of life and exercise tolerance in heart failure patients with preserved ejection fraction (HFpEF).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31096775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32458378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EAS COVERED: The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations.EX",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34074190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil, an inotropic agent that improves myocardial contractility by a novel mechanism, and vericiguat, a drug that stimulates soluble guanylate cyclase, are both being developed to treat patients with chronic HF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27545139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "fter the first generation of sGC stimulators like riociguat or lificiguat, new compound classes with different physicochemical and kinetic profiles were identified, like the sGC stimulators vericiguat or praliciguat.A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33395323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431706",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AIMS: Exploratory assessment of the potential benefits of the novel soluble guanylate cyclase stimulator vericiguat on health status in patients with heart failure (HF) with preserved ejection frac",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat, a novel stimulator of soluble guanylate cyclase (sGC), has shown promising results in patients with heart failure and reduced ejection fraction (HFrEF) in the recent VICTORIA trial. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34478114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat, a stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for worsening chronic heart failure in adults with left ventricular ejection fra",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34086190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32458378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat, a direct stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for symptomatic chronic heart failure (HF) and ejection fract",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33030703",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sion. Conversely, sGC stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, thus exerting a more physiological acti",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34410527",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "stimulators (riociguat and vericiguat) enhance sGC sensitivity to endogenous NO, and then exert a more physiological action. The phase 3 VICTOR",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34291399",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat has a dual mode of action on this axis, it both sensitizes sGC to low levels of NO, and can directly stimulate sGC in the absence of any endogenous NO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34478114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate (GMP) pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34157357",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that comp",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34074190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat stimulates sGC and cGMP production independent of nitric oxide (NO) and enhances the effects of NO by stabilizing the NO-sGC binding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33770393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat is an oral guanylate cyclase stimulator that through the recent VICTORIA trial showed a 10% relative difference in death from cardiovascular cause or hospitalization for heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33850913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " yielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that co",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34074190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "utic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF).AREAS COVERED: The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations.EXPERT OPINION: cGMP deficiency has deleterious effects on the he",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34074190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (N",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32458378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat (VERQUVO\u2122; Merck & Co, Bayer AG) is a soluble guanylate cyclase (sGC) stimulator being developed for the treatment of chronic heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33770393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat has been shown to directly stimulate sGC and enhance sGC sensitivity to endogenous NO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29032136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " new treatment option for those in whom rehospitalization or recurrent outpatient intravenous diuretic treatment is a concern. Given high rates of nonadherence in HF patients, vericiguat represents an additional treatment option, especially for patients who do not tolerate available HF therapies.CONCLUSION: Vericiguat is a novel soluble guanylate cyclase stimulator that is sa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vericiguat, a novel stimulator of soluble guanylate cyclase (sGC), has shown promising results in patients with heart failure and reduced ejection fraction (HFrEF) in the recent VICTORIA trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34478114",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}